Mirum Pharmaceuticals to Host Investor Call on VISTAS Study Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy MIRM?
Source: Newsfilter
- Investor Call Announcement: Mirum Pharmaceuticals has announced an investor call scheduled for May 4, 2026, at 8:30 a.m. ET to discuss topline results from the VISTAS study on volixibat for patients with primary sclerosing cholangitis (PSC), aimed at enhancing investor understanding of the company's R&D progress.
- Study Results Focus: The call will highlight the findings related to volixibat, an IBAT inhibitor in late-stage development for PSC and primary biliary cholangitis (PBC), which could provide new treatment options for patients, thereby potentially impacting market perception positively.
- Company Overview: Mirum Pharmaceuticals specializes in rare diseases, with a portfolio that includes approved products like LIVMARLI® and CHOLBAM®, demonstrating its commitment to delivering breakthrough therapies for overlooked conditions and showcasing deep expertise in the rare disease sector.
- Clinical Pipeline Insights: Mirum's clinical pipeline features candidates such as brelovitug for chronic hepatitis delta virus and MRM-3379 for Fragile X syndrome, reflecting the company's strategic focus on advancing high-impact medicines through disciplined execution and collaboration within the rare disease ecosystem.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MIRM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MIRM
Wall Street analysts forecast MIRM stock price to rise
9 Analyst Rating
9 Buy
0 Hold
0 Sell
Strong Buy
Current: 97.310
Low
81.00
Averages
102.33
High
140.00
Current: 97.310
Low
81.00
Averages
102.33
High
140.00
About MIRM
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the treatment of rare diseases affecting children and adults. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal or Ctexli (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States, Canada and Japan. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. The Company is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Mirum Pharmaceuticals to Host Investor Call on VISTAS Study Results
- Investor Call Announcement: Mirum Pharmaceuticals has announced an investor call scheduled for May 4, 2026, at 8:30 a.m. ET to discuss topline results from the VISTAS study on volixibat for patients with primary sclerosing cholangitis (PSC), aimed at enhancing investor understanding of the company's R&D progress.
- Study Results Focus: The call will highlight the findings related to volixibat, an IBAT inhibitor in late-stage development for PSC and primary biliary cholangitis (PBC), which could provide new treatment options for patients, thereby potentially impacting market perception positively.
- Company Overview: Mirum Pharmaceuticals specializes in rare diseases, with a portfolio that includes approved products like LIVMARLI® and CHOLBAM®, demonstrating its commitment to delivering breakthrough therapies for overlooked conditions and showcasing deep expertise in the rare disease sector.
- Clinical Pipeline Insights: Mirum's clinical pipeline features candidates such as brelovitug for chronic hepatitis delta virus and MRM-3379 for Fragile X syndrome, reflecting the company's strategic focus on advancing high-impact medicines through disciplined execution and collaboration within the rare disease ecosystem.
See More
Mirum Pharmaceuticals' AZURE-1 Study Achieves Key Endpoint
- Clinical Trial Success: Mirum Pharmaceuticals reported that in the Phase 2b portion of its AZURE-1 study, brelovitug demonstrated strong antiviral activity at Week 24, with 100% of patients in the 300 mg weekly group and 75% in the 900 mg every four weeks group achieving a virologic response, indicating its effectiveness in treating chronic hepatitis delta virus (HDV).
- Primary Endpoint Achieved: The primary composite endpoint, which includes virologic response and normalization of liver enzyme ALT, was achieved in 45% and 35% of patients in the respective dose groups, while none in the delayed treatment group, highlighting brelovitug's therapeutic potential.
- Good Tolerability: Over the 24-week observation period, continued reductions in viral levels and liver enzyme markers were observed, supporting brelovitug's potential as a standalone therapy for HDV, potentially offering new treatment options for patients.
- Stock Price Fluctuation: Mirum's shares closed at $91.49 on Friday, down 0.50%, reflecting a relatively muted market reaction despite the positive clinical trial results, which may indicate investor caution regarding future studies and market acceptance.
See More
Vertex and Mirum Pharmaceuticals Market Dynamics
- Vertex Financial Growth: Vertex Pharmaceuticals reported a record annual revenue of $12 billion in 2025, marking a 9% increase primarily driven by its dominance in cystic fibrosis (CF) therapies, with projected sales for 2026 expected to reach between $12.95 billion and $13.1 billion, solidifying its market leadership.
- Mirum Profitability Outlook: Mirum Pharmaceuticals achieved revenue of $521.3 million in 2025, a 54% increase, with Livmarli contributing $360 million, and forecasts for 2026 sales between $630 million and $650 million, indicating strong growth potential in the rare liver disease market.
- New Drug Development Progress: Mirum is conducting four potential registrational trials with key data expected over the next 18 months, and positive results could significantly expand its market reach, particularly in treating chronic hepatitis delta virus (HDV).
- Acquisition Strategy: Mirum completed its $820 million acquisition of Bluejay Therapeutics in January 2023 to enhance its pipeline with breakthrough therapies, which could generate over $750 million in annual revenue if successful, further strengthening its competitive position in the market.
See More
Vertex and Mirum: Biotech Investment Opportunities
- Mirum Revenue Growth: Mirum has successfully commercialized Livmarli, achieving $521.3 million in revenue for 2025, a 54% increase, with Livmarli contributing $360 million, up 69%, indicating strong demand in the rare liver disease market, and forecasts sales of $630 million to $650 million in 2026, further solidifying its market position.
- Pipeline Potential: Mirum expects four potential registrational readouts over the next 18 months, particularly studies targeting chronic hepatitis delta virus; positive results could significantly expand its market coverage and enhance overall company valuation.
- Strategic Significance of Bluejay Acquisition: Mirum's $820 million acquisition of Bluejay Therapeutics adds brelovitug, which holds Breakthrough Therapy status, targeting HDV with no current approved therapies, potentially generating over $750 million in annual revenue and enhancing market competitiveness.
- Vertex Market Dominance: Vertex received FDA approval to expand the label for Trikafta and Alyftrek, covering 95% of U.S. cystic fibrosis patients, with 2025 revenue reaching $12 billion and expected growth to $12.95 billion to $13.1 billion in 2026, reinforcing its leadership in the biotech sector.
See More
Mirum Pharmaceuticals: A Rising Star in Biotech
- Sales Growth: Mirum Pharmaceuticals experienced a 50% year-over-year increase in net product sales in Q4 2025, with Livmarli's sales soaring 69% to $360 million, indicating strong market demand in the rare disease treatment sector and enhancing financial stability.
- R&D Spending Plans: Although the company anticipates negative free cash flow in 2026, management aims to quickly return to positive cash flow by 2027, reflecting confidence in its future product pipeline and commitment to ongoing investment.
- Clinical Trial Progress: Mirum plans to report results from four pivotal clinical studies over the next 18 months, including Phase 3 data expected in Q2 2026, which could positively impact the stock price and further enhance market recognition of its potential.
- Market Valuation Potential: The peak sales estimates for Mirum's pipeline candidates exceed $4 billion, while the company's current market cap is around $5.8 billion; if its therapies succeed, Mirum could be valued at approximately $26 billion based on the average price-to-sales ratio of 6.4 in the biotech industry, indicating significant investment opportunities.
See More
Mirum Pharmaceuticals to Report Four Key Clinical Readouts in Next 18 Months
- Sales Growth: Mirum Pharmaceuticals experienced a 50% year-over-year increase in net product sales in Q4 2025, with Livmarli sales soaring 69% to $360 million, which enabled the company to generate positive free cash flow in 2025, indicating strong market demand and business sustainability.
- Clinical Trial Plans: The company plans to report four pivotal clinical study results over the next 18 months, including top-line data from a Phase 3 study evaluating volixibat for Primary Sclerosing Cholangitis expected in Q2 2026, which will significantly impact its future market performance.
- Market Potential Assessment: Peak sales estimates for Mirum's pipeline candidates exceed $4 billion, while the company's current market cap is around $5.8 billion; if its therapies succeed, Mirum could be valued at approximately $26 billion based on the average price-to-sales ratio of 6.4 in the biotech sector, highlighting its substantial growth potential.
- R&D Spending Impact: Although increased R&D spending will result in negative free cash flow this year, management expects to quickly return to positive free cash flow by 2027, reflecting confidence in its R&D pipeline and anticipated future profitability.
See More
Mirum Pharmaceuticals to Host Investor Call on VISTAS Study Results
- Investor Call Announcement: Mirum Pharmaceuticals has announced an investor call scheduled for May 4, 2026, at 8:30 a.m. ET to discuss topline results from the VISTAS study on volixibat for patients with primary sclerosing cholangitis (PSC), aimed at enhancing investor understanding of the company's R&D progress.
- Study Results Focus: The call will highlight the findings related to volixibat, an IBAT inhibitor in late-stage development for PSC and primary biliary cholangitis (PBC), which could provide new treatment options for patients, thereby potentially impacting market perception positively.
- Company Overview: Mirum Pharmaceuticals specializes in rare diseases, with a portfolio that includes approved products like LIVMARLI® and CHOLBAM®, demonstrating its commitment to delivering breakthrough therapies for overlooked conditions and showcasing deep expertise in the rare disease sector.
- Clinical Pipeline Insights: Mirum's clinical pipeline features candidates such as brelovitug for chronic hepatitis delta virus and MRM-3379 for Fragile X syndrome, reflecting the company's strategic focus on advancing high-impact medicines through disciplined execution and collaboration within the rare disease ecosystem.
See More
Mirum Pharmaceuticals' AZURE-1 Study Achieves Key Endpoint
- Clinical Trial Success: Mirum Pharmaceuticals reported that in the Phase 2b portion of its AZURE-1 study, brelovitug demonstrated strong antiviral activity at Week 24, with 100% of patients in the 300 mg weekly group and 75% in the 900 mg every four weeks group achieving a virologic response, indicating its effectiveness in treating chronic hepatitis delta virus (HDV).
- Primary Endpoint Achieved: The primary composite endpoint, which includes virologic response and normalization of liver enzyme ALT, was achieved in 45% and 35% of patients in the respective dose groups, while none in the delayed treatment group, highlighting brelovitug's therapeutic potential.
- Good Tolerability: Over the 24-week observation period, continued reductions in viral levels and liver enzyme markers were observed, supporting brelovitug's potential as a standalone therapy for HDV, potentially offering new treatment options for patients.
- Stock Price Fluctuation: Mirum's shares closed at $91.49 on Friday, down 0.50%, reflecting a relatively muted market reaction despite the positive clinical trial results, which may indicate investor caution regarding future studies and market acceptance.
See More
Vertex and Mirum Pharmaceuticals Market Dynamics
- Vertex Financial Growth: Vertex Pharmaceuticals reported a record annual revenue of $12 billion in 2025, marking a 9% increase primarily driven by its dominance in cystic fibrosis (CF) therapies, with projected sales for 2026 expected to reach between $12.95 billion and $13.1 billion, solidifying its market leadership.
- Mirum Profitability Outlook: Mirum Pharmaceuticals achieved revenue of $521.3 million in 2025, a 54% increase, with Livmarli contributing $360 million, and forecasts for 2026 sales between $630 million and $650 million, indicating strong growth potential in the rare liver disease market.
- New Drug Development Progress: Mirum is conducting four potential registrational trials with key data expected over the next 18 months, and positive results could significantly expand its market reach, particularly in treating chronic hepatitis delta virus (HDV).
- Acquisition Strategy: Mirum completed its $820 million acquisition of Bluejay Therapeutics in January 2023 to enhance its pipeline with breakthrough therapies, which could generate over $750 million in annual revenue if successful, further strengthening its competitive position in the market.
See More
Vertex and Mirum: Biotech Investment Opportunities
- Mirum Revenue Growth: Mirum has successfully commercialized Livmarli, achieving $521.3 million in revenue for 2025, a 54% increase, with Livmarli contributing $360 million, up 69%, indicating strong demand in the rare liver disease market, and forecasts sales of $630 million to $650 million in 2026, further solidifying its market position.
- Pipeline Potential: Mirum expects four potential registrational readouts over the next 18 months, particularly studies targeting chronic hepatitis delta virus; positive results could significantly expand its market coverage and enhance overall company valuation.
- Strategic Significance of Bluejay Acquisition: Mirum's $820 million acquisition of Bluejay Therapeutics adds brelovitug, which holds Breakthrough Therapy status, targeting HDV with no current approved therapies, potentially generating over $750 million in annual revenue and enhancing market competitiveness.
- Vertex Market Dominance: Vertex received FDA approval to expand the label for Trikafta and Alyftrek, covering 95% of U.S. cystic fibrosis patients, with 2025 revenue reaching $12 billion and expected growth to $12.95 billion to $13.1 billion in 2026, reinforcing its leadership in the biotech sector.
See More
Mirum Pharmaceuticals: A Rising Star in Biotech
- Sales Growth: Mirum Pharmaceuticals experienced a 50% year-over-year increase in net product sales in Q4 2025, with Livmarli's sales soaring 69% to $360 million, indicating strong market demand in the rare disease treatment sector and enhancing financial stability.
- R&D Spending Plans: Although the company anticipates negative free cash flow in 2026, management aims to quickly return to positive cash flow by 2027, reflecting confidence in its future product pipeline and commitment to ongoing investment.
- Clinical Trial Progress: Mirum plans to report results from four pivotal clinical studies over the next 18 months, including Phase 3 data expected in Q2 2026, which could positively impact the stock price and further enhance market recognition of its potential.
- Market Valuation Potential: The peak sales estimates for Mirum's pipeline candidates exceed $4 billion, while the company's current market cap is around $5.8 billion; if its therapies succeed, Mirum could be valued at approximately $26 billion based on the average price-to-sales ratio of 6.4 in the biotech industry, indicating significant investment opportunities.
See More
Mirum Pharmaceuticals to Report Four Key Clinical Readouts in Next 18 Months
- Sales Growth: Mirum Pharmaceuticals experienced a 50% year-over-year increase in net product sales in Q4 2025, with Livmarli sales soaring 69% to $360 million, which enabled the company to generate positive free cash flow in 2025, indicating strong market demand and business sustainability.
- Clinical Trial Plans: The company plans to report four pivotal clinical study results over the next 18 months, including top-line data from a Phase 3 study evaluating volixibat for Primary Sclerosing Cholangitis expected in Q2 2026, which will significantly impact its future market performance.
- Market Potential Assessment: Peak sales estimates for Mirum's pipeline candidates exceed $4 billion, while the company's current market cap is around $5.8 billion; if its therapies succeed, Mirum could be valued at approximately $26 billion based on the average price-to-sales ratio of 6.4 in the biotech sector, highlighting its substantial growth potential.
- R&D Spending Impact: Although increased R&D spending will result in negative free cash flow this year, management expects to quickly return to positive free cash flow by 2027, reflecting confidence in its R&D pipeline and anticipated future profitability.
See More
